🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07514377
Active, not recruiting Observational

JiGenerations Health Cohort Study:Parental Exposure and Intergenerational Health in China

NCT07514377 · tracked via the Priya Life Science China tracker
Sponsor
National Research Institute for Family Planning, China
Phase
Observational
Started
2025-08-01
Last updated
2026-04-07

Condition(s) studied

Environmental ExposureFertilityHealth Problems in PregnancyAdverse Pregnancy OutcomesBirth DefectsChild DevelopmentMetabolic AbnormalityGrowth RetardationOverweight and ObesityNon-alcoholic Fatty Liver Disease

Investigational drug(s) / intervention(s)

N/A (Observational Study)

N/A (Observational Study): This is an observational cohort study. No interventions are assigned. Groups are defined based on different condition or exposure.

Study summary

The growing recognition of maternal health's impact on offspring necessitates large-scale prospective cohort studies spanning the maternal-child life cycle. This study establishes a family-centered birth cohort of 100,000 Chinese participants, tracking from preconception through offspring adolescence to investigate early-life health trajectories and intergenerational transmission of diseases, health status, and psychological-behavioral patterns. Data collection includes biospecimens (placenta, cord blood, breast milk, blood, urine, feces) and multi-omics analysis (genomic, proteomic, metabolomic, microbiomic), alongside clinical information from preconception, pregnancy, birth through childhood (0-14 years). The cohort covers 24 stratified sites across China, incorporating real-time environmental monitoring (air pollution, meteorological data) and sociogeographic factors. Targeting reproductive-age couples (18-45 years) and their offspring, the study addresses multigenerational health linkages, urban-rural disparities, and regional diversity from 2025 to 2039. By integrating genetic, environmental and lifestyle data, this research will identify critical intervention windows and mechanisms for chronic disease transmission across generations, supporting China's "Healthy China" initiative and developing targeted strategies for population health and aging.

Eligibility

Sex
ALL
Min age
1 Day
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Parental Generation: Eligible participants include couples of reproductive age who undergo free pre-pregnancy eugenic health examinations, or pregnant women registered for prenatal care at healthcare institutions during early pregnancy (≤14 weeks). The participants are aged 18-45 years old and have mobile phones and internet (computer) devices. All participants must provide informed consent and commit to long-term follow-up. The participants have no serious neuropsychiatric disorders, with sufficient understanding and expression to complete the survey. 2. Offspring Generation: Newborns whose parents participated in pre-pregnancy eugenic health checks and/or maternal prenatal examinations are enrolled in the cohort upon parental (guardian) consent. Designated hospitals will provide expedited medical services, free physical examinations, free child healthcare, and free psychological counseling to ensure comprehensive follow-up spanning infancy, preschool, school age, and early adolescence (0-14 years). Exclusion Criteria: 1. Intellectual disability or other serious mental disorders; 2. Suffering from serious underlying diseases and may have a significant impact on pregnancy outcome; 3. Those with poor compliance and difficulty in follow-up.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
National Research Institute for Family Planning Beijing Beijing Municipality

More National Research Institute for Family Planning, China trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07514377 on ClinicalTrials.gov ↗ ← All trials in China